| Place of Origin: | China |
|---|---|
| Brand Name: | HNB |
| Certification: | ISO |
| Model Number: | Alprostadil |
| Minimum Order Quantity: | 1KG |
| Price: | Negotiable |
| Packaging Details: | Aluminum foil bag |
| Delivery Time: | Usually7-10days |
| Payment Terms: | L/C, D/A, D/P, T/T, , MoneyGram |
| Supply Ability: | 5000kg/Month |
| CAS: | 745-65-3 | Mf: | C20H34O5 |
|---|---|---|---|
| MW: | 354.481 | Specification: | ≥98% |
| Appearance: | White Powder | Purity: | 99%,99%min |
| Shelf Life: | 2 Years | Grade: | Medical Grade,Phamaceutical Grade,Medicine & Tech,USP BP FCC EP |
API Pharmaceutical Prostaglandin E1 PGE1 alprostadil powder CAS 745-65-3
| Product Name: | Prostaglandin E1 |
| Synonyms: |
|
| CAS: | 745-65-3 |
| MF: | C20H34O5 |
| MW: | 354.481 |
The Introductction
The Application & Function
Alprostadil injection can treat limb ulcers caused by chronic arterial occlusive disease and limb resting pain caused by microvascular circulation disorders, and improve cardiovascular and cerebrovascular microcirculation disorders. Antithrombotic therapy after organ transplantation is used to inhibit thrombus formation in the transplanted blood vessels. Patent ductus arteriosus in children with congenital heart disease is used to relieve hypoxemia and maintain catheter blood flow to wait for surgical treatment.
Alprostadil injection is an intravenous alprostadil (prostaglandin E1) preparation with lipid microspheres as the drug carrier. Due to the encapsulation of lipid microspheres, alprostadil (prostaglandin E1) is not easy to be inactivated, and has the targeting characteristics of easy distribution to damaged blood vessels, so as to play the role of this product in blood vessel dilation and inhibition of platelet aggregation. In addition, this product also has the effect of stabilizing liver cell membrane and improving liver function.
1. Alprostadil injection can treat limb ulcers caused by chronic arterial obliterans (thromboangiitis obliterans, obliterans arteriosclerosis, etc.) and limb resting pain caused by minor vascular circulation disorders, and improve cardiovascular and cerebrovascular microcirculation disorders.
4, for the adjuvant treatment of chronic hepatitis.
The COA
| Item | Specification | Results |
| APPEARANCE | WHITE | CONFORMS |
| SOLUBILITY | FREELY SOLUBLE IN CHLOROFORM;SOLUBLE IN WATER OR METHANOL | CONFORMS |
| PH | 5.0-7.2 | 6.51 |
| LOSS ON DRYING | ≤4.5% | 3.10% |
| RESIDUEON IGNITION | ≤2.5% | 0.281% |
| HEAVY METALS | ≤20PPM | <15PPM |
| TYRAMINE | ≤0.35% | 0.051% |
| RELATED COMPOSITIONS | TYLOSIN A ≥80% A+B+C+D ≥95% | 93% 98% |
| Conclusion | Confirm with the standard |